New antibiotic JKN2501 enters first human tests
NCT ID NCT07207291
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the safety and tolerability of a new antibiotic called JKN2501 in 66 healthy adults in China. Participants receive either the drug or a placebo by IV infusion, and researchers monitor for side effects and how the drug moves through the body. The goal is to see if it is safe enough to study further for treating bacterial infections like urinary tract, abdominal, and respiratory infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JKN2501 (an experimental antibiotic given by IV infusion)
What this could lead to
If safe, this could lead to a new antibiotic for bacterial infections that are hard to treat.
What could go wrong
This is a very early Phase 1 trial in only 66 healthy people, so it is not yet tested in patients. The drug may cause side effects or fail in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third hospital of Changsha
RECRUITINGChangsha, Hunan, 410035, China
Contact Phone: •••-•••-•••• Email: •••••@•••••